Trinity Biotech secured a $7.0 million investment from Perceptive Credit Holdings III, L.P., comprising $2.5 million in new debt and $4.5 million of capitalized interest under an amendment to its credit agreement dated August 12, 2026. The company also regained compliance with Nasdaq’s minimum bid price requirement as of August 7, 2026, after maintaining a closing bid price of at least $1.00 per ADS for ten consecutive business days ending August 6, 2026. Preliminary revenues for the quarter ended June 30, 2026 were approximately $10.5 million. Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions.
